Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Efficacy and Effectiveness of the Herbal Medicinal Product BNO 1016 in the Management of Acute Rhinosinusitis in the Context of Antibiotic Stewardship

Version 1 : Received: 9 December 2022 / Approved: 19 December 2022 / Online: 19 December 2022 (04:05:48 CET)

A peer-reviewed article of this Preprint also exists.

Bittner, C.B.; Steindl, H.; Abramov-Sommariva, D.; Plach, M.; Abels, C.; Bachert, C. Efficacy and Effectiveness of the Herbal Medicinal Product BNO 1016 in the Management of Acute Rhinosinusitis in the Context of Antibiotic Stewardship. Postgraduate Medicine 2023, 1–8, doi:10.1080/00325481.2023.2234274. Bittner, C.B.; Steindl, H.; Abramov-Sommariva, D.; Plach, M.; Abels, C.; Bachert, C. Efficacy and Effectiveness of the Herbal Medicinal Product BNO 1016 in the Management of Acute Rhinosinusitis in the Context of Antibiotic Stewardship. Postgraduate Medicine 2023, 1–8, doi:10.1080/00325481.2023.2234274.

Abstract

(1) Background: To substantiate the clinical efficacy and investigate the real-world effectiveness of the herbal medicinal product BNO 1016 in acute rhinosinusitis (ARS) in the context of antibiotic stewardship. (2) Methods: Clinical efficacy: We performed a meta-analysis of the clinical trials ARhiSi-1 and ARhiSi-2 comprising 676 patients, analysing the reduction of the Major Symptom Score (MSS) and improvement of SNOT-20. Real-world effectiveness: In addition, we performed a retrospective cohort study including 203,382 patients, comparing the real-life effectiveness of BNO 1016 in reducing ARS-related adverse outcomes in comparison to antibiotics and several other established therapies. (3) Results: Clinical efficacy: Treatment with BNO 1016 ameliorated symptoms of ARS by reducing MSS by 1.9 points (p<0.0001) and improved quality of life (QoL) for patients by improving SNOT-20 by 3.5 points (p=0.001) in comparison to placebo. In patients with moderate/severe symptoms, the positive effects of BNO 1016 were even more pronounced (MSS: –2.3 points (p<0.0001); SNOT-20: –4.9 points (p=0.0158)) compared to placebo. Real-world effectiveness: Treatment with BNO 1016 was as effective or significantly more effective in reducing the risk for adverse ARS-related outcomes such as follow-up antibiotic prescriptions, sick leave ≥7 days or medical appointments due to ARS, especially when compared to antibiotics. (4) Conclusions: BNO 1016 is a safe and effective treatment for ARS that can help reduce the overuse of antibiotics.

Keywords

BNO 1016; antibiotics; herbal medicine; sinusitis; phytotherapy

Subject

Medicine and Pharmacology, Pharmacology and Toxicology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.